Massachusetts GIC drops obesity-only GLP-1 coverage for non-Medicare members

Massachusetts' Group Insurance Commission (GIC) has ended coverage of GLP-1 medicines prescribed only for obesity for its non-Medicare members as of June 30, 2026, and closed the prescribing part of its Vida Health arrangement at the same time ^[1][2]. Beginning July 1, members must work with their own provider and request prior authorization through CVS Caremark, the plan's pharmacy benefit manager, and coverage can be approved only when the prescription is tied to a qualifying FDA-approved medical condition ^[1][2].

The GIC covers more than 220,000 subscribers and 460,000 members ^[1]. Its published list of qualifying conditions, current as of June 17, 2026, covers three uses ^[1]:

• Non-cirrhotic MASH/NASH with moderate to advanced (F2-F3) fibrosis. There is no BMI requirement, because the FDA approved this use in both overweight/obese and non-overweight patients ^[1].
• Risk reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Requires a baseline BMI of at least 27 kg/m² ^[1].
• Treatment of moderate to severe obstructive sleep apnea in adults with obesity. Requires a current BMI of at least 30 kg/m² ^[1].

The GIC describes these as examples of qualifying conditions, mentioning heart (cardiovascular) disease, sleep apnea and certain liver conditions such as MASH/NASH, and says the list can change at any time ^[1]. Its notice names Wegovy, Zepbound and Saxenda as examples of the weight-loss medicines affected ^[1].

If a prescription is for weight loss only, the GIC says it will not be covered and the member pays the full cost out of pocket. If the prescription is for weight loss plus a qualifying medical condition, the provider can request coverage, and the request is reviewed before a decision is made ^[1].

Diabetes treatment is not affected. Medicines used for diabetes, such as Ozempic or Mounjaro, remain covered, and members using them do not need to enroll in any special program ^[1].

Vida Health continues, but without prescribing. Members can still use health coaching, nutrition support, lifestyle guidance and registered dietitian services; Vida will no longer prescribe anti-obesity medicines, including GLP-1s, and will direct members to their current non-Vida prescriber or, for those without a physician, to the GIC network directory ^[1][2].

Medicare GIC members have a longer transition. Their GIC coverage for GLP-1 medicines prescribed for obesity continues through December 31, 2026. After that, coverage under GIC plans generally continues only for members who meet CMS-approved clinical criteria ^[2].

Medicare is also expected to launch a temporary demonstration, the Medicare GLP-1 Bridge Program, beginning July 1, 2026, though eligibility requirements, participating medicines, costs and administrative processes were still being finalized when that information was published ^[2]. The program is expected to give eligible Medicare Part D beneficiaries access to certain weight-loss GLP-1 medicines for a flat copay of about $50 a month ^[2].

Medicines expected to be included are Wegovy in injectable and tablet forms, Zepbound in the KwikPen only, and Foundayo. Ozempic is not expected to be part of the program, which is focused on weight management rather than diabetes treatment ^[2]. Expected eligibility includes enrollment in a Medicare Part D plan and prior authorization from a physician showing a BMI of 35 or higher; a BMI of 30 or higher with qualifying conditions; or a BMI of 27 or higher with pre-diabetes or certain cardiovascular conditions. Members already taking these medicines may be able to qualify using the BMI they had when treatment began ^[2].

Why it matters for patients

For non-Medicare GIC members who take a GLP-1 only for weight loss, the practical change is cost: the plan no longer pays, and the full price applies ^[1]. Members whose prescription also treats cardiovascular disease, sleep apnea or MASH/NASH may still get coverage, but only after their own provider submits a prior authorization request that is reviewed ^[1]. Anyone whose prescription came through Vida now needs a prescriber outside that program ^[1][2].

Members with diabetes are in a different position: their GLP-1 coverage is unchanged, and no special enrollment is required ^[1]. Medicare GIC members keep obesity coverage into 2027 and have time to learn whether the federal bridge program applies to them ^[2].

How many members will lose coverage, and what the medicines will cost them at retail, has not been disclosed ^[1][2]. Whether the GIC decision will be followed by other insurers has not been reported.

What happens next

• July 1, 2026: prior authorization through CVS Caremark takes effect for non-Medicare GIC members, and the Vida prescribing arrangement has ended ^[1][2].
• July 1, 2026: the Medicare GLP-1 Bridge Program is expected to begin, with final details still being worked out ^[2].
• December 31, 2026: GIC coverage of GLP-1 medicines prescribed for obesity ends for Medicare GIC members; after that date, coverage generally continues only for those meeting CMS-approved clinical criteria ^[2].